FindTrial
Sign In

Use of neutrophil lymphocyte ratio in predicting early requirement of invasive ventilation in COVID 19 patients

Predicting early requirement of invasive ventilation in COVID 19 patients using neutrophil lymphocyte ratio.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037632
Enrollment
80
Registered
2021-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Jesica maria Dsouza
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients age � 18 years. All the patients with a laboratory confirmation of COVID 19 infection(RTPCR)

Exclusion criteria

Exclusion criteria: Cases with no laboratory confirmation of COVID 19 infection. Patients with history of carcinoma lung.

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of NL ratio for predicting early requirement of invasive ventilation in COVID19 patients. To identify association of NL ratio with requirement of different types of oxygen therapy in COVID19 patients.Timepoint: 48 hours from admission—

Secondary

MeasureTime frame
To identify association of NL ratio with requirement of different types of oxygen therapy in COVID19 patients.Timepoint: 48 hours of admission—

Countries

Bahamas

Contacts

Public ContactJesica Maria Dsouza

Father muller medical college

priyamitali2000@yahoo.co.in9008420730

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026